safety profile Based on the analysis of pooled placebo-controlled clinical trials in adjunctive therapy in 1,308 patients with partial-onset seizures, a total.9 of patients randomised to lacosamide and.2 of patients randomised to placebo reported at least. Dizziness Treatment with lacosamide has been associated with dizziness which could increase the occurrence of accidental injury or falls. More details, warning: Last items in stock! Drug Interactions Vimpat can negatively interact with some drugs. 5.3 Preclinical safety data In the toxicity studies, the plasma concentrations of lacosamide obtained were similar or only marginally higher than those observed in patients, which leaves low or non-existing margins to human exposure. It is important that this drug is taken with the right dosage within a specified time period.
Lacosamide is effectively removed from plasma by haemodialysis. Lacosamide has a low protein binding of less than. Marketing authorisation number(s) EU/1/08/470/001 EU/1/08/470/002 EU/1/08/470/003 EU/1/08/470/004 EU/1/08/470/005 EU/1/08/470/006 EU/1/08/470/007 EU/1/08/470/008 EU/1/08/470/009 EU/1/08/470/010 EU/1/08/470/011 EU/1/08/470/012 EU/1/08/470/020 EU/1/08/470/021 EU/1/08/470/022 EU/1/08/470/023 EU/1/08/470/024 EU/1/08/470/025 EU/1/08/470/026 EU/1/08/470/027 EU/1/08/470/028 EU/1/08/470/029 EU/1/08/470/030 EU/1/08/470/031. A gradual withdrawal of the concomitant AED over at least 6 weeks is recommended. In vitro data show that CYP2C9, CYP2C19 and CYP3A4 are capable of catalysing the formation of the O-desmethyl metabolite but the main contributing isoenzyme has not been confirmed in vivo. In vitro data Data generally suggest that lacosamide has a low interaction potential. In adolescents and adults weighing 50 kg or more, a loading dose of 200 mg may be considered, but further dose titration ( 200 mg daily) should be performed with caution. Description: Pharmaceutical manufacturers make coupons available to patients who cannot afford their medications. Continue typing to refine. Lacosamide can also be initiated at the dose of 100 mg twice a day based on the physician's assessment of required seizure reduction versus potential side effects.
The patients had to present with unprovoked partial-onset seizures with or without secondary generalisation. Pharmacokinetics in special patient groups Gender Clinical trials indicate that gender does not have a clinically significant influence on the plasma concentrations of lacosamide. Lacosamide did not affect the AUC of midazolam (metabolised by CYP3A4, lacosamide given 200 mg twice a day but Cmax of midazolam was slightly increased (30 ).